ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "registry"

  • Abstract Number: 0454 • ACR Convergence 2020

    Anticytokine Therapies for Inflammatory Rheumatic Disease (IRD) Are Associated with Reduced Hospitalisation Following Community COVID-19 Infection; Results of the Trinity Rheumatology and Covid-19 Registry – TRACR

    Rachael Flood1, Richard Conway2, David Kane1 and Ronan Mullan1, 1Tallaght University Hospital, Dublin, Ireland, 2St James's Hospital, Dublin, Ireland

    Background/Purpose: Anticytokine biological disease modifying anti-rheumatic drugs (bDMARD), which are widely prescribed  for Inflammatory Rheumatological Diseases (IRD) are currently undergoing clinical trials for the treatment…
  • Abstract Number: 1029 • ACR Convergence 2020

    Clinical Characteristics of Patients with Axial Spondyloarthritis in China: Results from the ChinaAS Registry

    Jinmei Su1, Runsheng Wang2, Ping Zhu3, Yanhong Wang4, Shangzhu Zhang1, Linyi Peng1, Min Yang5, Ling Lei6, Li Qin7, Mengtao Li8 and Xiaofeng Zeng8, 1Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China (People's Republic), 2Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 3Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), 4Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), 5Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (People's Republic), 6Department of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), 7Department of Rheumatology, The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), 8Peking Union Medical College Hospital, Department of Rheumatology, Beijing, Beijing, China (People's Republic)

    Background/Purpose: The ChinaAS is a nationwide, multicenter registry of patients with axial spondyloarthritis (SpA) in China to facilitate research in epidemiology, pathogenesis, diagnosis and treatment…
  • Abstract Number: 0601 • ACR Convergence 2020

    The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases

    Kent Kwas Huston1, Simon Helfgott2, Scott Milligan3, Jasvinder Singh4, Nehad Soloman5, Brandon Weil3 and Colin Edgerton6, 1Kansas City Physician Partners, Kansas City, MO, 2BWH- HMS, Boston, MA, 3Trio Health, Louisville, CO, 4University of Alabama at Birmingham, Birmingham, AL, 5Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, 6Articularis Healthcare, Summerville, SC

    Background/Purpose: Persistence on therapy is an important consideration in rheumatic diseases. There are multiple treatment options that influence long term disease management and a better…
  • Abstract Number: 1142 • ACR Convergence 2020

    Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

    Rebecca Overbury1, Tracy Frech2, John Bohnsack3, CJ Inman1, Sara Stern1, Karen James1, Erin Treemarcki4 and Aimee Hersh4, 1University of Utah and Primary Children's Hospital, Salt Lake City, UT, 2University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, 3University of Utah and Primary Children's Hospital, Cincinnati, OH, 4University of Utah and Primary Children's Hospital, Salt Lake City

    Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…
  • Abstract Number: 0714 • ACR Convergence 2020

    Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry

    Daniel J Lovell1, Nikolay Tzaribachev2, Esi Morgan3, Gabriele Simonini4, Thomas Griffin5, Ekaterina Alexeeva6, John Bohnsack7, Andrew Zeft8, Gerd Horneff9, Richard Vehe10, Valda Stanevicha11, Stacey Tarvin12, Maria Trachana13, Adam Huber14, Daniel Kietz15, Ilonka Orban16, Jason Dare17, Ivan Foeldvari18, Pierre Quartier19, Alyssa Dominique20, Tzuyung Douglas Kou20, Robert Wong20, Alberto Martini21, Hermine Brunner3 and Nicolino Ruperto22, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Anna Meyer Children's Hospital, Firenze, Italy, 5Levine Children's Hospital, Charlotte, NC, 6Scientific Center of Children’s Health of RAMS, Moscow, Russia, 7University of Utah and Primary Children's Hospital, Cincinnati, OH, 8Cleveland Clinic, Cleveland, OH, 9Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 10University of Minnesota, Minneapolis, MN, 11Riga Stradins University, Riga, Latvia, 12Riley Children’s Health, Indianapolis, IN, 13Aristotle University of Thessaloniki, Thessaloníki, Greece, 14Dalhousie University, Halifax, NS, Canada, 15Children’s Hospital of Pittsburgh, Pittsburgh, PA, 16National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 17University of Arkansas for Medical Sciences, Little Rock, AR, 18Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, 19Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 20Bristol-Myers Squibb Company, Princeton, NJ, 21PRINTO, Istituto Giannina Gaslini, Genova, Italy, 22Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
  • Abstract Number: 1153 • ACR Convergence 2020

    Trends in Timing of Biologic Use for Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry

    Ginger Janow1, Timothy Beukelman2, Yukiko Kimura3, Rayfel Schneider4, Shalini Mohan5, Gail Rodich6 and Mary Beth Son7, 1Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ, 2University of Alabama at Birmingham, Birmingham, AL, 3Hackensack Meridian School of Medicine, Hackensack, NJ, 4University of Toronto, The Hospital for Sick Children, Toronto, Canada, 5Genentech, Inc., South San Francisco, CA, 6Genentech, Mill Valley, CA, 7Boston Children's Hospital, Boston, MA

    Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes.  There may…
  • Abstract Number: 0716 • ACR Convergence 2020

    Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study

    Ruud Verstegen1, Peter Shrader2, Stephen Balevic3, Timothy Beukelman4, Colleen Correll5, Anne Dennos6, Thomas Phillips2 and Brian Feldman1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2Duke University, Durham, 3Duke University Medical Center, Durham, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Minnesota, Minneapolis, MN, 6Duke University, Durham, NC

    Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…
  • Abstract Number: 1155 • ACR Convergence 2020

    Long-term Safety Profile of Anakinra in Patients with Systemic Juvenile Idiopathic Arthritis

    Gabriella Giancane1, Riccardo Papa1, Sebastiaan Vastert2, Francesca Bagnasco1, Joost Swart1, Pierre Quartier3, Jordi Anton4, Isabelle Kone Paut1, Sylvia Kamphuis1, Troels Herlin5, Helga Sanner1, Fabrizio De Benedetti6, Elena Tsitsami7, Susan Mary Nielsen1, Estefania Moreno1, Chiara Pallotti1, Karin Franck-Larsson8, Håkan Malmström8, Susanna Cederholm9, Nico Wulffraat1 and Nicolino Ruperto10, 1IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, 2University Medical Center Utrecht, Utrecht, Netherlands, 3Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, 4Sant Joan de Déu Hospital, Madrid, Spain, 5Aarhus University Hospital, Aarhus, Denmark, 6Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 7Aghia Sophia Childrens Hospital, Athens, Greece, 8Swedish Orphan Biovitrum, Stockholm, Sweden, 9Sobi, Stockholm, Sweden, 10PRINTO, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: To evaluate the long-term safety profile of anakinra in patients with systemic juvenile idiopathic arthritis (sJIA)Methods: Data from patients with sJIA according to the…
  • Abstract Number: 0734 • ACR Convergence 2020

    Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

    Jordan Jones1, Chelsey Smith2, Daniel J Lovell3 and Mara Becker4, 1Children's Mercy Kansas City, Kansas City, MO, 2Children's Mercy Kansas City, Holden, MO, 3PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Duke University School of Medicine, Durham, NC

    Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…
  • Abstract Number: 1162 • ACR Convergence 2020

    Comparison of Clinicopathologic and Imaging Features Between Chronic Nonbacterial Osteomyelitis and Its Mimickers: A Multi-national 450 Case-Control Study

    Yongdong Zhao1, Raymond Naden2, Melissa Oliver3, Zhaoyi Wang4, Eveline Wu5, Cassyanne Aguiar6, Jonathan Akikusa7, Ozge Basaran8, Kevin Cain1, Martina Capponi9, Nathan Donaldson10, Emily Fox11, Antonella Insalaco12, Annette Jansson13, Ummusen Kaya Akca14, Tzielan Lee15, Edoardo Marrani16, Kamran Mahmood17, Elizabeth Murray18, Farzana Nuruzzaman19, Karen Onel20, Manuela Pardeo12, Lauren Potts21, Nathan Rogers10, Anja Schnabel22, Gabriele Simonini23, Jennifer Soep10, Sara Stern24, Alexander Theos25, Yujuan Zhang26, Polly Ferguson27, Christian Hedrich28, Fatma Dedeoglu29, Hermann Girschick30, Ronald Laxer31 and Seza Ozen32, 1University of Washington, Seattle, WA, 2Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand, 3Department of Pediatric Rheumatology, Riley Children's Hospital, Carmel, IN, 4University of Washington, Bothell, WA, 5UNC Chapel Hill, Chapel Hill, NC, 6Children's Hospital of the King's Daughters/EVMS, Norfolk, VA, 7PRINTO, Istituto Giannina Gaslini, Genova, Italy, 8Hospital for Special Surgery, New York City, NY, 9IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 10Children's Hospital Colorado, Aurora, CO, 11Children's Mercy Kansas City, Kansas City, MO, 12Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 13Dr. von Hauner Children's Hospital, Munich, Germany, 14Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, 15Stanford University School of Medicine, Palo Alto, CA, 16University of Florence, Firenze, Italy, 17Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, England, United Kingdom, 18CRMO Patient Partner, New York, NY, 19Stony Brook Children's Hospital, Stony Brook, NY, 20Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, 21CRMO Patient Partner, Fort Collins, CO, 22Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, 23Anna Meyer Children's Hospital, Firenze, Italy, 24University of Utah and Primary Children's Hospital, Salt Lake City, UT, 25Georgetown University, DERWOOD, MD, 26Tufts Medical Center, Boston, MA, 27University of Iowa Carver College of Medicine, Iowa City, IA, 28University of Liverpool, Liverpool, United Kingdom, 29Boston Children's Hospital, Boston, MA, 30Vivantes Children’s Hospital, Wuerzburg, Germany, 31The Hospital for Sick Children, Toronto, ON, Canada, 32Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO) predominantly affects children and young adults. Classification criteria are not available and diagnostic criteria that have…
  • Abstract Number: 0801 • ACR Convergence 2020

    The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Xue Han2, Joe Zhuo2, Amy Schrader1, Nicole Middaugh1, Page Moore1 and Vadim Khaychuk2, 1Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
  • Abstract Number: 1283 • ACR Convergence 2020

    Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry

    Clara Moriano1, Jaime Calvo-Alén2, Iñigo Rúa-Figueroa3, Elvira Díez Álvarez1, Cristina Bermúdez4, Francisco J López-Longo5, Maria Galindo-Izquierdo6, Alejandro Olivé-Marqués7, Eva Tomero Muriel8, Antonio Fernandez-Nebro9, Mercedes Freire-González10, Olaia Fernandez-Berrizbeitia11, Ana Pérez Gómez12, Maria Esther Uriarte13, Carlos Marras Fernández-Cid14, Carlos Montilla Morales15, Gregorio Santos Soler16, Ricardo Blanco17, Manuel Rodríguez-Gómez18, Paloma Vela19, Alina Lucica Boteanu20, Francisco Javier Narváez21, Victor Martinez Taboada22, Blanca Hernández Cruz23, Jose Luis Andreu Sanchez24, Jose A Hernández-Beriain25, Lorena Expósito26, Raul Menor Almagro27, Mónica Ibañez-Barceló28, Ivan Castellvi29, Carlos Galisteo30, Enrique Raya31, VE Quevedo-Vila32, Tomás Vázquez33, J Ibáñez-Ruan34 and Jose Maria Pego-Reigosa35, 1Complejo Asistencial Universitario de León, León, Spain, 2Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, 4Research Unit Bioaraba, Vitoria, Spain, 5Hospital General Universitario Gregorio Marañón, Madrid, Spain, 6Hospital Universitario 12 de Octubre, Madrid, Spain, 7Hospital Germans Trias i Pujol, Barcelona, Spain, 8Hospital Universitario de la Princesa, Madrid, Madrid, Spain, 9University of Malaga, Malaga, Spain, 10CHU Coruña, Coruña, Spain, 11Basurto University Hospital, Bilbao, Spain, 12Hospital Universitario Príncipe Asturias, Alcalá de Henares, Madrid, Spain, 13Hospital Universitario Donostia, San Sebastian, Spain, 14Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 15Hospital Universitario de Salamanca, Salamanca, Spain, 16Hospital Marina Baixa, Alicante, Spain, 17Hospital Universitario Marques de Valdecilla, Santander, Spain, 18Hospital Complex of Ourense, Ourense, Spain, 19Hospital General Alicante, Alicante, Spain, 20PRINTO, Istituto Giannina Gaslini, Genova, Italy, 21Hospital Bellvitge, BARCELONA, Spain, 22Marqués de Valdecilla University Hospital, Santander, Spain, 23Universidad de Sevilla, Sevilla, Spain, 24Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 25Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 26Hospital Clinico Tenerife, Tenerife, Spain, 27Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, 28Hospital Son Llatzer, Mallorca, Spain, 29Hospital Santa Creu i Sant Pau, Barcelona, Spain, 30Hospital Parc Taulí, Barcelona, Spain, 31Hospital San Cecilio, Granada, Spain, 32Hospital Comarcal de Monforte, Lugo, Spain, 33Hospital Lucus Augusti, Lugo, Spain, 34Hospital Povisa, Vigo, Pontevedra, Spain, 35University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain

    Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences.To analyze the causes…
  • Abstract Number: 0802 • ACR Convergence 2020

    Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness

    Yoshiya Tanaka1, Hisashi Yamanaka2, Leslie Harrold3, Tin-chi Lin3, Ekta Agarwal4, Jose L Rivas5, Naonobu Sugiyama6, Jeffrey Greenberg7 and Mitsumasa Kishimoto8, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 2Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, 3Corrona, LLC, Waltham, MA, 4Pfizer, Inc., Princeton Jct, NJ, 5Pfizer SLU, Madrid, Spain, 6Pfizer Japan Inc, Tokyo, Japan, 7Corrona, LLC and NYU School of Medicine, Waltham, MA, 8Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

    Background/Purpose: There are several conventional synthetic, targeted synthetic and biological disease-modifying anti-rheumatic medications (DMARDs) approved for the treatment of rheumatoid arthritis (RA) in Japan. Little…
  • Abstract Number: 1335 • ACR Convergence 2020

    Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register

    Dominic Seet1, Li Wearn Koh2, Preeti Dhanasekaran3, Man Hua Aw4, Rosa Lim Mui San2, Siaw Ing Yeo4 and Manjari Lahiri1, 1National University Hospital, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4Singapore General Hospital, Singapore, Singapore

    Background/Purpose: To describe the demographic and clinical characteristics of patients with inflammatory arthritis (IA) initiating biologic disease modifying anti-rheumatic drugs (bDMARD) who use complementary and…
  • Abstract Number: 0803 • ACR Convergence 2020

    Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety

    Mitsumasa Kishimoto1, Yoshiya Tanaka2, Leslie Harrold3, Alina Onofrei3, Christine Barr4, Ekta Agarwal5, Jose L Rivas6, Naonobu Sugiyama7, Jeffrey Greenberg8 and Hisashi Yamanaka9, 1Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 3Corrona, LLC, Waltham, MA, 4Corrona, LLC, Albany, NY, 5Pfizer, Inc., Princeton Jct, NJ, 6Pfizer SLU, Madrid, Spain, 7Pfizer Japan Inc, Tokyo, Japan, 8Corrona, LLC and NYU School of Medicine, Waltham, MA, 9Sanno Medical Center, Tokyo, Japan, Tokyo, Japan

    Background/Purpose: There is limited information on the real-world safety of disease-modifying anti-rheumatic drugs (DMARDs) approved for treating rheumatoid arthritis (RA) in Japan. Using a Japanese…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.